The Prevention of Progression to Pancreatic Cancer Trial (The 3PC Trial)


Full Title

Preventing an Incurable Disease: The Prevention of Progression to Pancreatic Cancer Trial (The 3PC Trial) (DUHS IRB)


An intraductal papillary mucinous neoplasm (IPMN) is a growth in the main pancreatic duct or one of its side branches. IPMN may be precancerous or cancerous. This study will assess the drug sulindac to see if it can slow the progression of IPMN cysts of the pancreas.

Participants in this study will be randomly assigned to take sulindac or a placebo (inactive drug) orally (by mouth) twice a day for three years. The long-term goal of this study is to reduce the risk of developing pancreatic cancer in people with IPMN pancreatic cysts.

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have IPMN that has a high risk of becoming cancerous.
  • People who are already taking a non-steroidal anti-inflammatory drug (NSAID, such as ibuprofen or naproxen) or corticosteroid drug (such as prednisone) three or more times a week may not participate.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 21-85.


For more information and to ask about eligibility for this study, please contact the office of Dr. Kevin Soares at 212-639-3195.




Phase II (phase 2)

Investigator ID